|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kypta RM and Waxman J: Wnt/beta-catenin
signalling in prostate cancer. Nat Rev Urol. 9:418–428. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reya T and Clevers H: Wnt signalling in
stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barker N and Clevers H: Mining the Wnt
pathway for cancer therapeutics. Nat Rev Drug Discov. 5:997–1014.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kahn M: Can we safely target the WNT
pathway? Nat Rev Drug Discov. 13:513–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang Y, Hewitt SM, Liu S, Zhou X, Zhu H,
Zhou C, Zhang G, Quan L, Bai J and Xu N: Tissue microarray analysis
of human FRAT1 expression and its correlation with the subcellular
localisation of beta-catenin in ovarian tumours. Br J Cancer.
94:686–691. 2006.PubMed/NCBI
|
|
9
|
Wang Y, Liu S, Zhu H, Zhang W, Zhang G,
Zhou X, Zhou C, Quan L, Bai J, Xue L, et al: FRAT1 overexpression
leads to aberrant activation of beta-catenin/TCF pathway in
esophageal squamous cell carcinoma. Int J Cancer. 123:561–568.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo G, Mao X, Wang P, Liu B, Zhang X,
Jiang X, Zhong C, Huo J, Jin J and Zhuo Y: The expression profile
of FRAT1 in human gliomas. Brain Res. 1320:152–158. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo G, Kuai D, Cai S, Xue N, Liu Y, Hao J,
Fan Y, Jin J, Mao X, Liu B, et al: Knockdown of FRAT1 expression by
RNA interference inhibits human glioblastoma cell growth, migration
and invasion. PloS One. 8:e612062013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo G, Zhong CL, Liu Y, Xue N, Liu Y, Hao
J, Fan Y, Jin J, Mao X and Liu B: Overexpression of FRAT1 is
associated with malignant phenotype and poor prognosis in human
gliomas. Dis Markers. 2015:2897502015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo G, Liu B, Zhong C, Zhang X, Mao X,
Wang P, Jiang X, Huo J, Jin J, Liu X and Chen X: FRAT1 expression
and its correlation with pathologic grade, proliferation, and
apoptosis in human astrocytomas. Med Oncol. 28:1–6. 2011.
View Article : Google Scholar
|
|
14
|
Zhang Y, Yu JH, Lin XY, Miao Y, Han Y, Fan
CF, Dong XJ, Dai SD and Wang EH: Overexpression of Frat1 correlates
with malignant phenotype and advanced stage in human non-small cell
lung cancer. Virchows Arch. 459:255–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Han Y, Zheng R, Yu JH, Miao Y,
Wang L and Wang EH: Expression of Frat1 correlates with expression
of β-catenin and is associated with a poor clinical outcome in
human SCC and AC. Tumour Biol. 33:1437–1444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan Y, Yang Z, Miao X, Li D, Liu Z and
Zou Q: The clinical significance of FRAT1 and ABCG2 expression in
pancreatic ductal adenocarcinoma. Tumour Biol. 36:9961–9968. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jin R, Liu W, Menezes S, Yue F, Zheng M,
Kovacevic Z and Richardson DR: The metastasis suppressor NDRG1
modulates the phosphorylation and nuclear translocation of
β-catenin through mechanisms involving FRAT1 and PAK4. J Cell Sci.
127:3116–3130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH Image to ImageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
21
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chesire DR and Isaacs WB: Beta-catenin
signaling in prostate cancer: An early perspective. Endocr Relat
Cancer. 10:537–560. 2003. View Article : Google Scholar
|
|
23
|
Prajapati A and Gupta S, Mistry B and
Gupta S: Prostate stem cells in the development of benign prostate
hyperplasia and prostate cancer: Emerging role and concepts. Biomed
Res Int. 2013:1079542013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goksel G, Bilir A, Uslu R, Akbulut H,
Guven U and Oktem G: WNT1 gene expression alters in heterogeneous
population of prostate cancer cells; decreased expression pattern
observed in CD133+/CD44+ prostate cancer stem cell spheroids. J
BUON. 19:207–214. 2014.PubMed/NCBI
|
|
25
|
Jonkers J, Korswagen HC, Acton D, Breuer M
and Berns A: Activation of a novel proto-oncogene, Frat1,
contributes to progression of mouse T-cell lymphomas. EMBO J.
16:441–450. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jonkers J, Weening JJ, van der Valk M,
Bobeldijk R and Berns A: Overexpression of Frat1 in transgenic mice
leads to glomerulosclerosis and nephrotic syndrome, and provides
direct evidence for the involvement of Frat1 in lymphoma
progression. Oncogene. 18:5982–5990. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yost C, Farr GH III, Pierce SB, Ferkey DM,
Chen MM and Kimelman D: GBP, an inhibitor of GSK-3, is implicated
in Xenopus development and oncogenesis. Cell. 93:1031–1041. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jonkers J, van Amerongen R, van der Valk
M, Robanus-Maandag E, Molenaar M, Destrée O and Berns A: In vivo
analysis of Frat1 deficiency suggests compensatory activity of
Frat3. Mech Dev. 88:183–194. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
van Amerongen R, van der Gulden H, Bleeker
F, Jonkers J and Berns A: Characterization and functional analysis
of the murine Frat2 gene. J Biol Chem. 279:26967–26974. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li L, Yuan H, Weaver CD, Mao J, Farr GH
III, Sussman DJ, Jonkers J, Kimelman D and Wu D: Axin and Frat1
interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated
regulation of LEF-1. EMBO J. 18:4233–4240. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hay E, Faucheu C, Suc-Royer I, Touitou R,
Stiot V, Vayssière B, Baron R, Roman-Roman S and Rawadi G:
Interaction between LRP5 and Frat1 mediates the activation of the
Wnt canonical pathway. J Biol Chem. 280:13616–13623. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thomas GM, Frame S, Goedert M, Nathke I,
Polakis P and Cohen P: A GSK3-binding peptide from FRAT1
selectively inhibits the GSK3-catalysed phosphorylation of axin and
beta-catenin. FEBS Lett. 458:247–251. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hagen T, Cross DA, Culbert AA, West A,
Frame S, Morrice N and Reith AD: FRAT1, a substrate-specific
regulator of glycogen synthase kinase-3 activity, is a cellular
substrate of protein kinase A. J Biol Chem. 281:35021–35029. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Caspi M, Zilberberg A, Eldar-Finkelman H
and Rosin-Arbesfeld R: Nuclear GSK-3beta inhibits the canonical Wnt
signalling pathway in a beta-catenin phosphorylation-independent
manner. Oncogene. 27:3546–3555. 2008. View Article : Google Scholar : PubMed/NCBI
|
